cholangiocarcinoma
Oncology · 2024–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| futibatinib Treatment of locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement in patients who have progressed after at least one prior line… | Mar 2025 | Not recommended | input received Pancare Foundation · Liver Foundation · Rare Cancers Australia · Medical Oncology Group |
| futibatinib Locally advanced or metastatic cholangiocarcinoma in patients with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement who have progressed… | Nov 2025 | Not recommended | input received Session Addendum Cancers Australia · Pancare Foundation · Liver Foundation · Medical Oncology Group |
| ivosidenib Treatment of locally advanced or metastatic cholangiocarcinoma in patients with an IDH1 R132 mutation after at least one prior line of systemic therapy. | Jul 2024 | Not recommended | input received Pancare Foundation · Liver Foundation · Rare Cancers Australia · Medical Oncology Group |
Who spoke
Pancare Foundation · Liver Foundation · Medical Oncology Group · Rare Cancers Australia · Session Addendum Cancers Australia
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| futibatinibFutibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA1005 | recommended restricted | 2024-09 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| pemigatinibPEMAZYRE pemigatinib 13.5 mg tablet blister pack | 2022 | 3 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.